Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

BACKGROUND: We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein a...

Descripción completa

Detalles Bibliográficos
Autores principales: Viegas, Edna O., Kroidl, Arne, Munseri, Patricia J., Missanga, Marco, Nilsson, Charlotta, Tembe, Nelson, Bauer, Asli, Joachim, Agricola, Joseph, Sarah, Mann, Philipp, Geldmacher, Christof, Fleck, Sue, Stöhr, Wolfgang, Scarlatti, Gabriella, Aboud, Said, Bakari, Muhammad, Maboko, Leonard, Hoelscher, Michael, Wahren, Britta, Robb, Merlin L., Weber, Jonathan, McCormack, Sheena, Biberfeld, Gunnel, Jani, Ilesh V., Sandström, Eric, Lyamuya, Eligius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264478/
https://www.ncbi.nlm.nih.gov/pubmed/30496299
http://dx.doi.org/10.1371/journal.pone.0206838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264478/
https://www.ncbi.nlm.nih.gov/pubmed/30496299
http://dx.doi.org/10.1371/journal.pone.0206838

Ejemplares similares